{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"53.2","value":"44"},{"groupId":"OG001","lowerLimit":"40.8","upperLimit":"62.4","value":"51.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is defined as a \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"NUMBER","populationDescription":"Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.","reportingStatus":"POSTED","timeFrame":"Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)","title":"Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}